I am pleased with the acquistion.The (up front) price paid looks...

I am pleased with the acquistion.

The (up front) price paid looks very reasonable given how advanced the technology is (in terms of clinical trials and regulatory approvals), that it is still in the early phases of market adoption and the good reimbursement levels available.

I am sure the pricing is reflective of the existing and anticipated levels of market competition, plus the extra effort required to increase market share for what is a surgically complex operation.

There are other stated channel/cross-selling benefits as well which can only be good.

I would say well done Ellex, now they just need to capitalise upon it.

Also - appears from presentation wording that SLT sales into USA are going very well. So the previously anticipated $6-10m of additional revenues sounds achievable.

Looking forward to some guidance for 1H14 with bated breath.